Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Capital Expenditures (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Capital Expenditures for 3 consecutive years, with $11000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Capital Expenditures rose 266.67% year-over-year to $11000.0, compared with a TTM value of $18000.0 through Dec 2024, down 92.91%, and an annual FY2024 reading of $18000.0, down 92.91% over the prior year.
  • Capital Expenditures was $11000.0 for Q4 2024 at Oramed Pharmaceuticals, up from $5000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $308000.0 in Q4 2022 and bottomed at $2000.0 in Q1 2024.
  • Average Capital Expenditures over 3 years is $69818.2, with a median of $20000.0 recorded in 2022.
  • Peak annual rise in Capital Expenditures hit 323.4% in 2023, while the deepest fall reached 99.03% in 2023.
  • Year by year, Capital Expenditures stood at $308000.0 in 2022, then tumbled by 99.03% to $3000.0 in 2023, then skyrocketed by 266.67% to $11000.0 in 2024.
  • Business Quant data shows Capital Expenditures for ORMP at $11000.0 in Q4 2024, $5000.0 in Q3 2024, and $2000.0 in Q1 2024.